Entheon Biomedical is a listed (CSE:ENBI) company that aims to develop DMT for addiction treatment.
Entheon Biomedical
The company went public on the Canadian Securities Exchange (CSE) on the 12th of November.
From their website: “Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.“
The company is funded (in part) by Synaptic Ventures.
Key Staff
- Timothy Ko – CEO
- Brandon Schwabe – CFO
- Andrew Hegle – Director of Operations & CSO
- Matthew Johnson – Scientific Advisor
- Robin Carhart-Harris – Scientific Advisor
- Dennis McKenna – Scientific Advisor
- Christopher Timmermann – Scientific Advisor
Activities
B2B
B2C
Biotech
Topics of Interest
Addiction
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Ehave Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research (GlobeNewswire, 01 June 2022)Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT (Biospace, 15 March 2022)
Entheon Biomedical: Data and DMT among the keys to creating safe and effective treatments for patients battling addiction (, 26 November 2021)
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments (, 13 December 2021)